We are live on ! Find out more
IGC icon

IGC Pharma
IGC

36 hedge funds and large institutions have $1.14M invested in IGC Pharma in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

82% more capital inflows, than outflows

Capital inflows: $401K | Capital outflows: $220K

20% more funds holding

Funds holding: 30 → 36 (+6)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0.81% less ownership

Funds ownership: 5.2% → 4.39% (-0.81%)

Holders
36
Holders Change
+6
Holders Change %
+20%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
6
Reduced
5
Closed
4
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$50.8K
2
Virtu Financial
Virtu Financial
New York
+$6.45K
3
XTX Topco
XTX Topco
Cayman Islands
+$6.2K
4
Morgan Stanley
Morgan Stanley
New York
+$4.83K
5
HighTower Advisors
HighTower Advisors
Illinois
+$2.78K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$121K
2
Citadel Advisors
Citadel Advisors
Florida
-$78.1K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$8.98K
4
Dearborn Partners
Dearborn Partners
Illinois
-$6.94K
5
UBS Group
UBS Group
Switzerland
-$3.27K

IGC Hedge Fund Activity: Q1 2026 in Review

36 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2026, worth a combined $1.14M — down 16% from $1.36M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new IGC positions and 4 closed out — a net gain of 8 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $50.8K. The largest seller was Renaissance Technologies, cutting an estimated $121K.

  • 36 institutional investors held IGC Pharma (IGC) as of Q1 2026, up from 30 in Q4 2025.
  • Funds reported $1.14M of IGC Pharma stock for Q1 2026, down 16% quarter-over-quarter.
  • 12 funds opened new IGC Pharma positions in Q1 2026 and 4 closed out, a net change of +8 holders.
  • The largest IGC Pharma buyer in Q1 2026 was Geode Capital Management, an estimated $50.8K added.
  • The largest IGC Pharma seller in Q1 2026 was Renaissance Technologies, an estimated $121K sold.

Based on aggregated 13F filings for Q1 2026.